Learning from “Learning from Hackers”

Alongside colleagues (Enrico Coiera and Richard Day) from here in Sydney and (Kenneth Mandl) from near Boston in the US, I wrote an article for Science Translational Medicine in which we related the current system of “clinical trial evidence translation” to the very successful open source software movement. We highlighted the factors in that success - … Continue reading Learning from “Learning from Hackers”

Of exceptional importance – connecting patients to research

For quite some time, I’ve been very interested in the disconnect between the research being undertaken and the questions that people (especially patients and doctors) need answered. There is a huge disconnect between the two. The NEJM has published a short piece on a very well-funded institute, The Patient-Centered Outcomes Research Institute (PCORI), which will … Continue reading Of exceptional importance – connecting patients to research

Another approved drug may leave the market

Bevacizumab Treatment for Solid Tumors, February 2, 2011, Hayes 305 (5): 506 — JAMA Avastin is a really expensive (think 50K a year) and dangerous (people die more often) drug that has been shown to have marginal positive effects on the progression of cancer for some patients. It is a very difficult question to weigh … Continue reading Another approved drug may leave the market